WebApr 14, 2024 · Greenwich LifeSciences has a 52-week low of $6.82 and a 52-week high of $21.50. The stock’s fifty day simple moving average is $14.92 and its 200-day simple … WebOct 4, 2024 · Business Wire. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast …
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires …
WebApr 10, 2024 · 31/03 Greenwich LifeSciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre ... WebDec 1, 2024 · STAFFORD, Texas, December 01, 2024 -- ( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of... small law firm practice management software
GREENWICH LIFESCIENCES, INC. : Other Events (form 8-K)
WebApr 10, 2024 · Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients. WebApr 10, 2024 · A rating of 81 puts Greenwich Lifesciences Inc ( GLSI) near the top of the Healthcare sector according to InvestorsObserver . Greenwich Lifesciences Inc's score of 81 means that it ranks higher than 81% of stocks in the sector. In addition, its overall score of 57 ranks it higher than 57% of all stocks. GLSI has an Overall Score of 57. Webabout. management team; board of directors; technology. our gp2 cancer immunotherapy product; cancer and immunotherapy background; clinical trials. completed phase iib clinical trial sonic the werehog drawing